Gene:
ACYP2
acylphosphatase 2, muscle type

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for ACYP2

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1872328 185+29374G>A, 33217146G>A, 54395259G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs843748 186-28913G>A, 33324799G>A, 54502912G>A
G > A
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA24500

Details

Cytogenetic Location: chr2 : p16.2 - p16.2
GP mRNA Boundary: chr2 : 54342410 - 54532437
GP Gene Boundary: chr2 : 54332410 - 54535437
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
cisplatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
oxaliplatin

Curated Information ?

Publications related to ACYP2: 3

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2016. Kanai M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma. Pharmacogenetics and genomics. 2016. Vos Hanneke I, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature genetics. 2015. Xu Heng, et al. PubMed

LinkOuts

NCBI Gene:
98
OMIM:
102595
UCSC Genome Browser:
NM_138448
RefSeq RNA:
NM_138448
RefSeq Protein:
NP_612457
RefSeq DNA:
NT_022184
UniProtKB:
ACYP2_HUMAN (P14621)
Ensembl:
ENSG00000170634
GenAtlas:
ACYP2
GeneCard:
ACYP2
MutDB:
ACYP2
ALFRED:
LO004585W
HuGE:
ACYP2
ModBase:
P14621
HumanCyc Gene:
HS10161
HGNC:
180

Common Searches